ArticleJournal of cellular and molecular medicine2021
Astragaloside IV attenuates inflammatory response mediated by NLRP-3/calpain-1 is involved in the development of pulmonary hypertension.
Article in Journal of cellular and molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 52 citations in OpenAlex.
- Signaling pathways and targeted therapy for pulmonary hypertension.Signal transduction and targeted therapy · 2025Review
- The effects of sodium-glucose cotransporter 2 inhibitors on the 'forgotten' right ventricle.ESC heart failure · 2025Review
- Pulmonary hypertension: etiology and anti-inflammatory treatment pathways of natural products.Frontiers in pharmacology · 2025Review
- Natural terpenoids with therapeutic potential against pulmonary arterial hypertension.Frontiers in pharmacology · 2025Review
- Chinese Herbal Medicine in Hypoxic Pulmonary Hypertension Treatment: Mechanisms, Progress, and Future Directions.Drug design, development and therapy · 2025Review
- Saponins as potential novel NLRP3 inflammasome inhibitors for inflammatory disorders.Archives of pharmacal research · 2024Review
- Safflower Alleviates Pulmonary Arterial Hypertension by Inactivating NLRP3: A Combined Approach of Network Pharmacology and Experimental Verification.The clinical respiratory journal · 2024Article
- Otud6b induces pulmonary arterial hypertension by mediating the Calpain-1/HIF-1α signaling pathway.Cellular and molecular life sciences : CMLS · 2024Article
- Cell Death in Pulmonary Arterial Hypertension.International journal of medical sciences · 2024Review
- Astragaloside IV Protects against Shear Stress-Induced Glycocalyx Damage and Alleviates Abdominal Aortic Aneurysm by Regulating miR-17-3p/Syndecan-1.Analytical cellular pathology (Amsterdam) · 2024Article
- Astragaloside IV ameliorate acute alcohol-induced liver injury in miceAnnals of medicine · 2023Article
- Qiqilian ameliorates vascular endothelial dysfunction by inhibiting NLRP3-ASC inflammasome activationPharmaceutical biology · 2023Article
- Astragaloside IV restrains pyroptosis and fibrotic development of pulmonary artery smooth muscle cells to ameliorate pulmonary artery hypertension through the PHD2/HIF1α signaling pathway.BMC pulmonary medicine · 2023Article
- Natural Products for the Treatment of Pulmonary Hypertension: Mechanism, Progress, and Future Opportunities.Current issues in molecular biology · 2023Review
- Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1/2 pathway.Journal of cellular and molecular medicine · 2023Article
- Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases.Drug design, development and therapy · 2023Review
- Review on the protective mechanism of astragaloside IV against cardiovascular diseases.Frontiers in pharmacology · 2023Review
- The BCL2/BAX/ROS pathway is involved in the inhibitory effect of astragaloside IV on pyroptosis in human umbilical vein endothelial cells.Pharmaceutical biology · 2022Article
- Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.BMC pulmonary medicine · 2022Article
- Traditional Herbal Medicine Discovery for the Treatment and Prevention of Pulmonary Arterial Hypertension.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Inflammation eventually leads to pulmonary arterial hypertension (PAH). Astragaloside IV(AS-IV) has a protective effect on pulmonary hypertension, but the specific protective mechanism has been unclear until now. Therefore, in this study, our aim was to investigate the mechanisms underlying the effects of AS-IV on PAH. In vivo, male Sprague-Dawley (SD) rats were injected intraperitoneally with monocrotaline (MCT, 60 mg/kg) and treated with AS-IV (40 mg/kg, 80 mg/kg), MCC950 and MDL-28170. In vitro, human pulmonary artery endothelial cells (HPAECs) were treated with monocrotaline pyrrole (MCTP, 60 μg/mL). The protein expression levels of NLRP-3, caspase-1, ASC, IL-18, IL-1β and calpain-1 were measured in vivo and/or in vitro. The results showed that AS-IV decreased the protein expression levels of NLRP-3, caspase-1, ASC, IL-18, IL-1β and calpain-1 in vivo and/or vitro. In conclusion, in this study the results suggested that AS-IV could inhibit monocrotaline-induced pulmonary arterial hypertension via the NLRP-3/calpain-1 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.